Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt, Philipp; Ebeling, Peter; Buttkereit, Ulrike; Brandhorst, Dieter; Opalka, Bertram; Poser, Miriam; Müller, Siemke; Flasshove, Michael; Moritz, Thomas; Seeber, Siegfried; Nowrousian, Mohammad Resa

Schütt, Philipp; Ebeling, Peter; Buttkereit, Ulrike; Brandhorst, Dieter; Opalka, Bertram; Poser, Miriam; Müller, Siemke; Flasshove, Michael; Moritz, Thomas; Seeber, Siegfried; Nowrousian, Mohammad Resa.

Affiliation

Schütt P; Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Hufelandstrasse 55, 45122, Essen, Germany. philipp.schuett@uni-essen.de

Ann Hematol ; 84(9): 594-600, 2005 Sep.

Article in En | MEDLINE | ID: mdl-15744524

Subject(s)

Dexamethasone/administration & dosage; Multiple Myeloma/drug therapy; Receptors, Interleukin-2/blood; Salvage Therapy/methods; Thalidomide/administration & dosage; Aged; Cause of Death; Drug Administration Schedule; Drug Therapy, Combination; Humans; Middle Aged; Multiple Myeloma/diagnosis; Multiple Myeloma/mortality; Prognosis; Survival Analysis; Thalidomide/toxicity; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Dexamethasone / Receptors, Interleukin-2 / Salvage Therapy / Multiple Myeloma Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Humans / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2005 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links